TechTalk: Bridging Efficacy and Safety Through Advanced DMPK
Friday, October 9 at 15:30 BST | 16:30 CEST | 10:30 EDT | 07:30 PDT
While ADME-related attrition has dramatically declined from roughly 40% in the 1980s and 90s to 10–15% today, sub-optimal DMPK properties remain a primary driver of drug candidate failure. This TechTalk explores how modern DMPK science serves as the foundational bridge between pharmacology and safety assessment, empowering teams to drive smarter, risk-informed candidate selection.
Join industry experts Roger Melton and Dr. Matt Hutzler from Inotiv as they unpack the persistent hurdles of drug exposure, including dissolution, solubility, permeability, and first-pass metabolism and examine the dominant categories of DMPK-driven attrition. Discover how implementing strategic, tiered screening cascades can filter out high-risk assets early, optimizing resource allocation before committing to definitive, high-cost studies.
Certificate of attendance
If you attend the live TechTalk, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand TechTalk, you can request a certificate of attendance by emailing editor@selectscience.net.
TechTalk details
- Cost: Free to attend
- Location: Online
- Duration: 20 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on-demand recording once it becomes available.
Speakers
Who should attend?
- Discovery and preclinical scientists
- Medicinal chemists
- DMPK/ADME scientists
- Toxicologists
- Pharmacologists
- Project/program leaders involved in selection of drug candidates for preclinical development
What will this webinar cover?
- Understand how DMPK connects pharmacology (efficacy/biomarkers) and safety assessment through exposure science, and why it is central to risk-based candidate progression.
- Learn how tiered DMPK assays can efficiently triage candidates from hit-to-lead through candidate selection.
- Identify the major categories of DMPK-related candidate failure.
- Apply a framework for assessing developability by integrating in vitro / in vivo pharmacology and DMPK information with safety data to estimate therapeutic index.